Advances on the relationship of innate immune response and atherosclerosis

Progress in Biochemistry and Biophysics

Volumn 40, Issue 5, 2013, Pages 406-415

  Zhao, Guo Jun ^a   Tang, Chao Ke ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Atherosclerosis; Innate immune cells; NOD like receptors; Toll like receptors

Indexed keywords

EID: 84881189225     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1206.2012.00466     Document Type: Review

References (79)

1. Yin K, Liao D F, Tang C K. ATP-binding membrane cassette transporter Al (ABCA1): a possible link between inflammation and reverse cholesterol transport. Mol Med, 2010, 16(9-10):438-449
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med, 1999, 340(2):115-126
3. Spirig R, Tsui J, Shaw S. The emerging role of TLR and innate immunity in cardiovascular disease. Cardiol Res Pract, 2012, 2012:181394
4. Olkkonen V M. Macrophage oxysterols and their binding proteins: roles in atherosclerosis. Curr Opin Lipidol, 2012, 23(5):462-470
5. Fotis L, Giannakopoulos D, Stamogiannou L, et al. Intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 in children. Do they play a role in the progression of atherosclerosis?. Hormones (Athens), 2012, 11(2):140-146
6. Zhou B R, Pan Y, Zhai Z M. Fibrinogen and P-selectin expression in atherosclerosis model of Sprague Dawley rat. Chin Med J (Engl), 2011, 124(22):3768-3772
7. Gu L, Okada Y, Clinton S K, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell, 1998, 2(2):275-281
8. Kim J Y, Kim W J, Kim H, et al. The stimulation of CD 147 induces MMP-9 expression through ERK and NF-kappaB in macrophages: implication for atherosclerosis. Immune Netw, 2009, 9(3):90-97
9. Brocheriou I, Maouche S, Durand H, et al. Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: implication in atherosclerosis. Atherosclerosis, 2011, 214(2):316-324
10. Hansson G K, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol, 2006, 6(7):508-519
11. Kzhyshkowska J, Neyen C, Gordon S. Role of macrophage scavenger receptors in atherosclerosis. Immunobiology, 2012, 217(5):492-502
12. Yu H, Ha T, Liu L, et al. Scavenger receptor A (SR-A) is required for LPS-induced TLR4 mediated NF-kappaB activation in macrophages. Biochim Biophys Acta, 2012, 1823(7):1192-1198
13. Yin K, Deng X, Mo Z C, et al. Tristetraprolin-dependent post-transcriptional regulation of inflammatory cytokine mRNA expression by apolipoprotein A-I: role of ATP-binding membrane cassette transporter AI and signal transducer and activator of transcription 3. J Biol Chem, 2011, 286(16):13834-13845
14. Yin K, Chen W J, Zhou Z G, et al. Apolipoprotein A-I inhibits CD40 proinflammatory signaling via ATP-binding cassette transporter A1-mediated modulation of lipid raft in macrophages. J Atheroscler Thromb, 2012, 19(9):823-836
15. Siefert S A, Sarkar R. Matrix metalloproteinases in vascular physiology and disease. Vascular, 2012, 20(4):210-216
16. Sjoberg S, Shi G P. Cysteine protease cathepsins in atherosclerosis and abdominal aortic aneurysm. Clin Rev Bone Miner Metab, 2011, 9(2):138-147
17. Kaartinen M, van der Wal A C, van der Loos C M, et al. Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. J Am Coll Cardiol, 1998, 32(3):606-612
18. Sun J, Sukhova G K, Wolters P J, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med, 2007, 13(6):719-724
19. Libby P, Shi G P. Mast cells as mediators and modulators of atherogenesis. Circulation, 2007, 115(19):2471-2473
20. Levick S P, Melendez G C, Plante E, et al. Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res, 2011, 89(1):12-19
21. Hans C P, Feng Y, Naura A S, et al. Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy. Cardiovasc Pathol, 2011, 20(2):e57-e68
22. Tchougounova E, Lundequist A, Fajardo I, et al. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem, 2005, 280(10):9291-9296
23. Caughey G H, Raymond W W, Wolters P J. Angiotensin II generation by mast cell alpha-and beta-chymases. Biochim Biophys Acta, 2000, 1480(1-2):245-257
24. Heikkila H M, Latti S, Leskinen M J, et al. Activated mast cells induce endothelial cell apoptosis by a combined action of chymase and tumor necrosis factor-alpha. Arterioscler Thromb Vase Biol, 2008, 28(2):309-314
25. Lee M, Calabresi L, Chiesa G, et al. Mast cell chymase degrades apoE and apoA-Q in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler Thromb Vase Biol, 2002, 22(9):1475-1481
26. Lee M, Sommerhoff C P, von Eckardstein A, et al. Mast cell tryptase degrades HDL and blocks its function as an acceptor of cellular cholesterol. Arterioscler Thromb Vasc Biol, 2002, 22(12):2086-2091
27. Lappalainen H, Laine P, Pentikainen M O, et al. Mast cells in neovascularized human coronary plaques store and secrete basic fibroblast growth factor, a potent angiogenic mediator. Arterioscler Thromb Vasc Biol, 2004, 24(10):1880-1885
28. Steffel J, Akhmedov A, Greutert H, et al. Histamine induces tissue factor expression: implications for acute coronary syndromes. Circulation, 2005, 112(3):341-349
29. Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol, 2008, 9(5):503-510
30. Yokoyama W M, Kim S, French A R. The dynamic life of natural killer cells. Annu Rev Immunol, 2004, 22:405-429
31. Whitman S C, Rateri D L, Szilvassy S J, et al. Depletion of natural killer cell function decreases atherosclerosis in low-density lipoprotein receptor null mice. Arterioscler Thromb Vase Biol, 2004, 24(6):1049-1054
32. Leclercq A, Houard X, Philippe M, et al. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J Leukoc Biol, 2007, 82(6):1420-1429
33. Sugiyama S, Kugiyama K, Aikawa M, et al. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vase Biol, 2004, 24(7):1309-1314
34. Woollard K J, Suhartoyo A, Harris E E, et al. Pathophysiological levels of soluble P-selectin mediate adhesion of leukocytes to the endothelium through Mac-1 activation. Circ Res, 2008, 103(10):1128-1138
35. Zemecke A, Bot I, Djalali-Talab Y, et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res, 2008, 102(2):209-217
36. Liu P, Yu Y R, Spencer J A, et al. CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden. Arterioscler Thromb Vase Biol, 2008, 28(2):243-250
37. Shaposhnik Z, Wang X, Weinstein M, et al. Granulocyte macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions. Arterioscler Thromb Vase Biol, 2007, 27(3):621-627
38. Packard R R, Maganto-Garcia E, Gotsman I, et al. CD11c (+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circ Res, 2008, 103 (9):965-973
39. Smale S T. Transcriptional regulation in the innate immune system. Curr Opin Immunol, 2012, 24(1):51-57
40. Olive C. Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants. Expert Rev Vaccines, 2012, 11(2):237-256
41. Langefeld T, Mohamed W, Ghai R, et al. Toll-like receptors and NOD-like receptors: domain architecture and cellular signalling. Adv Exp Med Biol, 2009, 653:48-57
42. Fresno M, Alvarez R, Cuesta N. Toll-like receptors, inflammation, metabolism and obesity. Arch Physiol Biochem, 2011, 117(3):151-164
43. Michelsen K S, Wong M H, Shah P K, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA, 2004, 101(29):10679-10684
44. Bjorkbacka H, Kunjathoor V V, Moore K J, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med, 2004, 10(4):416-421
45. Monaco C, Gregan S M, Navin T J, et al. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation, 2009, 120(24):2462-2469
46. Katsargyris A, Klonaris C, Bastounis E, et al. Toll-like receptor modulation: a novel therapeutic strategy in cardiovascular disease?. Expert Opin Ther Targets, 2008, 12(11):1329-1346
47. Sabroe I, Parker L C, Dower S K, et al. The role of TLR activation in inflammation. J Pathol, 2008, 214(2):126-135
48. Jiang J, Mo Z C, Yin K, et al. Epigallocatechin-3-gallate prevents TNF-alpha-induced NF-kappaB activation thereby upregulating ABCA1 via the Nrf2/Keapl pathway in macrophage foam cells. Int J Mol Med, 2012, 29(5):946-956
49. Cao D L, Yin K, Mo Z C, et al. Prog Biochem Biophys, 2010, 37(5):540-548
50. Cole J E, Georgiou E, Monaco C. The expression and functions of toll-like receptors in atherosclerosis. Mediators Inflamm, 2010, 2010:393946
51. Edfeldt K, Swedenborg J, Hansson G K, et al. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation, 2002, 105(10):1158-1161
52. Ishida B Y, Blanche P J, Nichols A V, et al. Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H. J Lipid Res, 1991, 32(4):559-568
53. Gu H, Tang C, Peng K, et al. Effects of chronic mild stress on the development of atherosclerosis and expression of Toll-like receptor 4 signaling pathway in adolescent apolipoprotein E knockout mice. J Biomed Biotechnol, 2009, 2009:613879
54. Shinohara M, Hirata K, Yamashita T, et al. Local overexpression of Toll-like receptors at the vessel wall induces atherosclerotic lesion formation: synergism of TLR2 and TLR4. Arterioscler Thromb Vase Biol, 2007, 27(11):2384-2391
55. Mizoguchi E, Orihara K, Hamasaki S, et al. Association between Toll-like receptors and the extent and severity of coronary artery disease in patients with stable angina. Coron Artery Dis, 2007, 18(1):31-38
56. Seimon T A, Nadolski M J, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab, 2010, 12(5):467-482
57. Kim S, Takahashi H, Lin W W, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature, 2009, 457(7225):102-106
58. Funk J L, Feingold K R, Moser A H, et al. Lipopolysaccharide stimulation of RAW 264.7 macrophages induces lipid accumulation and foam cell formation. Atherosclerosis, 1993, 98(1):67-82
59. Lee J G, Lim E J, Park D W, et al. A combination of Lox-1 and Noxl regulates TLR9-mediated foam cell formation. Cell Signal, 2008, 20(12):2266-2275
60. Bar-Or A, Nuttall R K, Duddy M, et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain, 2003, 126(Pt 12):2738-2749
61. Shapiro S D, Campbell E J, Kobayashi D K, et al. Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-gamma. J Clin Invest, 1990, 86(4):1204-1210
62. Fabunmi R P, Sukhova G K, Sugiyama S, et al. Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells: a potential protective mechanism in plaque stability. Circ Res, 1998, 83(3):270-278
63. Cole J E, Navin T J, Cross A J, et al. Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci USA, 2011, 108(6):2372-2377
64. Guarda G, Braun M, Staehli F, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity, 2011, 34(2):213-223
65. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol, 2009, 27:229-265
66. Mariathasan S, Monack D M. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol, 2007, 7(1):31-40
67. Lopez-Castejon G, Brough D. Understanding the mechanism of IL-lbeta secretion. Cytokine Growth Factor Rev, 2011, 22(4):189-195
68. Barker B R, Taxman D J, Ting J P. Cross-regulation between the IL-lbeta/IL-18 processing inflammasome and other inflammatory cytokines. Curr Opin Immunol, 2011, 23(5):591-597
69. Duewell P, Kono H, Rayner K J, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature, 2010, 464(7293):1357-1361
70. Yajima N, Takahashi M, Morimoto H, et al. Critical role of bone marrow apoptosis-associated speck-like protein, an inflammasome adaptor molecule, in neointimal formation after vascular injury in mice. Circulation, 2008, 117(24):3079-3087
71. Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1 beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vase Biol, 2003, 23(4):656-660
72. Elhage R, Jawien J, Rudling M, et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res, 2003, 59(1):234-240
73. Devlin C M, Kuriakose G, Hirsch E, et al. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci USA, 2002, 99(9):6280-6285
74. Elhage R, Jawien J, Rudling M, et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res, 2003, 59(1):234-240
75. Whitman S C, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E (-/-) mice through release of interferon-gamma. Circ Res, 2002, 90(2):E34-E38
76. Vandanmagsar B, Youm Y H, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med, 2011, 17(2):179-188
77. Masters S L, Dunne A, Subramanian S L, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-lbeta in type 2 diabetes. Nat Immunol, 2010, 11(10):897-904
78. Lee M S. Role of innate immunity in diabetes and metabolism: recent progress in the study of inflammasomes. Immune Netw, 2011, 11(2):95-99
79. Gearing A J. Targeting Toll-like receptors for drug development: a summary of commercial approaches. Immunol Cell Biol, 2007, 85(6):490-494